Sinopril Co

Quick links to important sections

Sinopril Co

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinopril Co

Quick Facts

Property Description
Active Ingredients Lisinopril, Hydrochlorothiazide
Form Tablet (Oral dosage form)
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor / Thiazide Diuretic
Common Purpose Management of high blood pressure (Hypertension)
Origin Synthetic/Derived

What Type of Medicine is Sinopril Co?

Sinopril Co is classified as a fixed-dose combination (FDC) antihypertensive agent, a specific type of medication designed to manage elevated blood pressure. This preparation is a synthetic/derived pharmaceutical entity supplied for oral use as a single tablet. The FDC structure strategically combines two compounds from different pharmacological classes into one unit to support consistent adherence to the treatment strategy. The use of a single-pill combination helps simplify complex medication regimens for patients. This simplified structure is clinically recognized for contributing to better long-term cardiovascular management.


What is Sinopril Co Made Of? (Active Ingredients and Class)

The medication contains two distinct active ingredients: Lisinopril and Hydrochlorothiazide. Lisinopril is an Angiotensin-Converting Enzyme (ACE) Inhibitor, while Hydrochlorothiazide is categorized as a Thiazide Diuretic. The combination of these two agents is a standard and well-supported strategy in medical practice, with the formulation known by common brands such as Zestoretic and Prinzide in addition to the generic name. Combination therapy incorporating an ACE inhibitor and a diuretic is a highly effective strategy for initial and ongoing hypertension treatment. This demonstrates the recognized efficacy of combining these specific medication types, which target complementary pathways in blood pressure regulation.


What is the General Purpose of This Combination?

The primary general purpose of Sinopril Co is to provide a comprehensive, dual-action method for achieving sustained control over high blood pressure (hypertension). This is typically used in a scenario where a patient requires the benefits of both an agent that promotes vasodilation and an agent that controls fluid volume. The combination works synergistically: Lisinopril promotes the relaxation of blood vessel walls, and Hydrochlorothiazide decreases the fluid volume in the bloodstream through increased diuresis. By addressing both the resistance of the blood vessels and the circulating fluid volume, the preparation offers a robust approach to supporting cardiovascular stability.

What side effects are possible with Sinopril Co?

Possible Side Effects and Safety Information

The official safety profile for Sinopril Co (Lisinopril/Hydrochlorothiazide) is established by government regulatory agencies and documents adverse reactions by frequency and physiological system.


Documented Adverse Reactions and Frequency

Adverse effects are categorized based on their incidence in clinical data, aligning with regulatory standards:

  • Common (1% to 10%): Include Dizziness, Headache, Cough, and Fatigue. These often affect the Nervous System and General well-being.
  • Uncommon (0.1% to 1%): Reactions such as Syncope (fainting), Palpitation, Nausea, and Hyperkalemia are noted in the regulatory documents.
  • Rare or Very Rare (< 0.1%): Include serious conditions like Angioedema and Intestinal Angioedema, as well as Pancreatitis.

Critical Safety Constraints and Special Populations

Specific limitations and serious adverse reactions are explicitly detailed in official labeling:

  • Serious Adverse Reactions: Angioedema (swelling of the face or throat) is considered a critical adverse reaction. Acute angle-closure glaucoma and Acute respiratory distress syndrome (ARDS) are also documented serious, though infrequent, risks.
  • Time-Related Patterns: Dizziness and Orthostatic Hypotension are more likely to occur at the start of treatment or during dose changes. The risk of Non-melanoma skin cancer is associated with the long-term use of the hydrochlorothiazide component.
  • Population Restrictions: The medicine is strictly contraindicated during pregnancy due to the risk of fetal harm. It is also contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min), and safety for pediatric use has not been established.

Regulatory Safety Summary: The documented safety framework formally categorizes all potential effects and defines specific constraints, particularly emphasizing risks in sensitive populations and the necessary caution in individuals with pre-existing conditions like severe renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation classifies overdose of Sinopril Co (Lisinopril/Hydrochlorothiazide) as a potentially severe event driven by two primary pharmacological risks: profound hemodynamic instability and critical electrolyte derangement.

Documented Overdose Manifestations

Classification Manifestations and Systems Affected
Cardiovascular Profound Hypotension (excessively low blood pressure), Fainting, Tachycardia or Bradycardia
Metabolic/Renal Severe Fluid and Electrolyte Imbalance (e.g., Hypokalemia), Acute Renal Failure, Muscle Cramps
Neurological Drowsiness, Confusion, Seizures

Regulator-Mandated Emergency Actions

The most prominent clinical finding is Profound Hypotension, which may lead to collapse. Due to these risks, regulatory guidance requires that an individual seek immediate medical attention or call emergency services if an overdose is suspected. Urgent medical intervention is specifically mandated if manifestations include collapse, seizures, or difficulty breathing. Treatment is exclusively Symptomatic and Supportive, as no specific antidote is known. The Lisinopril component is documented as being removable by Hemodialysis, and general supportive care includes volume expansion with Intravenous Fluids.

Therapeutic Uses of Sinopril Co

What Sinopril Co Treats: Main Uses and Benefits

Sinopril Co (Lisinopril/Hydrochlorothiazide) is commonly used to help with conditions presenting with systemic or localized discomfort related to the cardiovascular system. This medicine is applied in scenarios where symptoms create noticeable physiological strain and additional management of discomfort is required. This usage is relevant for high blood pressure (hypertension).


Managing High Blood Pressure (Hypertension)

This medication is commonly used across conditions characterized by periods of heightened symptoms related to blood pressure fluctuation, such as headaches or dizziness. It helps address symptom clusters that may become intense or disruptive, providing supportive relief that contributes to improved comfort during symptomatic periods. The primary areas of focus are relevant for managing hypertension and assisting with systemic discomfort.

“This medicine may assist with maintaining a sense of stability when symptoms are more noticeable.”

Quick Fact: Supports management of disruptive symptom clusters.


Providing Additional Symptomatic Support

Sinopril Co is relevant in contexts marked by increased discomfort or tension and provides support that helps ease the overall symptom burden associated with chronic conditions. It helps the patient during difficult episodes by easing discomfort. This medication is commonly used in clinical settings where short-term symptomatic assistance is needed to help patients cope more steadily.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Sinopril Co (Lisinopril/Hydrochlorothiazide) is officially approved for use in adult patients with hypertension. Eligibility for the medicine is strictly defined by regulatory contraindications and population-specific restrictions.


Contraindicated Populations

Use is strictly forbidden for patients who are hypersensitive to either Lisinopril, Hydrochlorothiazide, or any sulfonamide-derived drugs. It is also contraindicated in patients with a history of angioedema related to a previous ACE inhibitor, or those with hereditary or idiopathic angioedema. The medicine must not be used in patients with anuria (inability to pass urine).


Age and Physiological Status

Use is contraindicated during the second and third trimesters of pregnancy due to risk of harm to the developing fetus, and must be discontinued immediately upon detection of pregnancy. The combination product is not recommended for the pediatric population as its safety and effectiveness have not been established. Use while breastfeeding is not recommended.


Condition and Concomitant Drug Restrictions

Eligibility is limited by organ function and other treatments. Sinopril Co is contraindicated for use with aliskiren in patients with diabetes mellitus or renal impairment. It must also not be used within 36 hours of taking a neprilysin inhibitor (e.g., sacubitril). Caution is required for patients with impaired hepatic function or specific heart valve conditions like aortic stenosis.

What should I know about interactions with other medicines?

The official regulatory documents for Sinopril Co (Lisinopril/Hydrochlorothiazide) detail interaction patterns that define mandatory restrictions and co-administration constraints. These interactions are classified based on their potential for pharmacokinetic (drug level alteration) or pharmacodynamic (effect alteration) consequences.

Mandatory Prohibitions and Restrictions

Interacting Substance Regulatory Constraint Outcome (Official Description)
Sacubitril/Valsartan Contraindicated Significantly increased risk of severe angioedema. A 36-hour waiting period is mandatory between administrations.
Aliskiren Contraindicated Prohibited in patients with diabetes mellitus or moderate-to-severe renal impairment.
Lithium Caution Required Co-administration leads to reduced renal clearance of Lithium, resulting in dangerously increased serum levels and risk of toxicity.

Interactions Affecting Electrolytes and Renal Function

The combination of Lisinopril and Hydrochlorothiazide interacts with several substances by affecting electrolyte balance and kidney function. Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene) and Potassium supplements/salt substitutes may cause a significant rise in serum potassium levels (hyperkalemia).

Co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may attenuate the blood pressure-lowering effect and increase the risk for deterioration of renal function, particularly in elderly or volume-depleted patients. Agents that affect the mammalian target of rapamycin (mTOR Inhibitors) also pose a documented increased risk for angioedema. Furthermore, Alcohol may potentiate the hypotensive effects of this medicine.

Mechanism of Action

Sinopril Co (Lisinopril) functions as a competitive inhibitor of the angiotensin-converting enzyme (ACE), a peptidyl dipeptidase located primarily on the luminal surface of endothelial cells, particularly within the pulmonary circulation and kidneys. This inhibition blocks the conversion of the inactive decapeptide angiotensin I to the active octapeptide angiotensin II

.

The molecular consequence of ACE inhibition is a decrease in circulating and tissue concentrations of Angiotensin II. As Angiotensin II normally acts as a direct vasoconstrictor and stimulates the secretion of aldosterone from the adrenal cortex, its reduction leads to two key intracellular consequences. First, a reduction in the activation of Angiotensin II Type 1 ( AT1) receptors on vascular smooth muscle cells results in vasodilation (relaxation of arterioles). Second, decreased aldosterone secretion reduces the reabsorption of sodium and water in the renal collecting duct, promoting their excretion, while concurrently modulating potassium ion retention.

Downstream, the inhibition of ACE also prevents the degradation of bradykinin, a potent vasodepressor peptide, leading to elevated local bradykinin levels which contributes to vasodilation. System-level physiological modulation occurs through the combined effects of reduced vasoconstrictor activity and decreased fluid volume regulation, resulting in a systemic decrease in peripheral vascular resistance.

Dosage and Administration Information

Sinopril Co is designed for oral administration as a fixed-dose combination (FDC) tablet. The approved regimen requires once-daily use, with administration typically occurring in the morning to support consistent control over a 24-hour period. The tablet may be taken with or without food and must be swallowed whole, as preparation by crushing or chewing is not indicated in the labeling.

Official Dosing and Use Context

This medication is generally not indicated for initial therapy; the fixed-dose combination is reserved for use in patients whose blood pressure is not adequately controlled by the individual components, lisinopril or hydrochlorothiazide, used alone. Initial dosing ranges vary (e.g., 10 mg/12.5 mg or 20 mg/12.5 mg) depending on the patient's prior monotherapy.

Treatment follows a titration schedule, meaning the dose may be gradually adjusted over time. Adjustments are typically made every two to three weeks based on the clinical response, and the dose should not exceed the maximum recommended daily limit of 80 mg lisinopril / 50 mg hydrochlorothiazide.

Population and Procedural Constraints

Specific procedural constraints apply to initiation: existing diuretic agents should generally be discontinued for 2–3 days before starting Sinopril Co. Furthermore, the FDC tablet is not recommended for use in severe renal dysfunction, and its administration in moderate renal impairment is restricted until titration of the individual components confirms the appropriate fixed dose is required. The safety and efficacy for use in the pediatric population have not been established.

Recent Clinical Evidence

Research evidence / Overview of studies for Sinopril Co

This section provides a transparent overview of the official research structure for Sinopril Co (Lisinopril/Hydrochlorothiazide). It describes the types of studies conducted and the focus of their measurements, but it is not intended to provide clinical guidance or an individual prediction of how the medicine may affect a patient.


Evidence for Use in Managing High Blood Pressure (Essential Hypertension)

The research examined by regulators was conducted in individuals with essential high blood pressure. These studies involved Randomized Controlled Trials (RCTs), which were applied in research exploring short-term measurements of blood pressure. Researchers monitored a core outcome: the change in systolic and diastolic blood pressure (SBP and DBP) numbers from the start of the study.

Research describes patterns observed in the studies where the proportion of participants assigned to the combination treatment who met pre-defined blood pressure criteria was noted to be higher than those receiving either lisinopril or hydrochlorothiazide alone. This evidence contributes to understanding symptom patterns and provides insight into short-term changes.

Comparison of Combination Therapy in Clinical Research

Research has explored the clinical approach of combining an ACE inhibitor and a diuretic. Studies monitored how the fixed-dose combination performed when compared to taking either lisinopril or hydrochlorothiazide alone (monotherapy), sometimes against a placebo. Findings indicate that the fixed-dose combination was associated with achieving lower blood pressure measurements compared to the use of either component alone. This evidence contributes to understanding how the combination has been studied in the broader research landscape.


Long-Term Evidence and Durability of Response

The clinical trials that evaluated this specific fixed-dose medicine often included follow-up durations that were limited, typically ranging from 8 to 12 weeks for initial efficacy measurements, with some maintenance studies extending up to one year.


Key Limitations and What Remains Under Study

The evidence landscape, while robust for short-term blood pressure control, presents certain limitations. The core measurements often rely on blood pressure (a surrogate outcome), and evidence is limited from multi-year trials that track major cardiovascular events specifically for this fixed combination. Furthermore, data for certain groups are still emerging. This includes the pediatric population (children and adolescents), where the medicine has not been evaluated in clinical trials.

Key Studies & References

  1. Summary of Product Characteristics (SPC) - Lisinopril/Hydrochlorothiazide (EU Regulatory Document)
  2. 2023 ESH Guidelines for the management of arterial hypertension (Relevant for combination therapy rationale)

Frequently Asked Questions (FAQ)

Common questions about Sinopril Co (FAQ)


Q: How quickly does Sinopril Co start working after taking it?

Official product information indicates that the blood pressure-lowering effect from the lisinopril component generally begins within two hours after a dose is taken. This initial action contributes to its overall effect over time.


Q: How long does the effect of one dose of Sinopril Co last in the body?

The drug is prescribed for once-daily use, as the official documentation notes that the blood pressure-lowering effect of lisinopril lasts for at least 24 hours. This duration is the basis for its prescription as a once-daily medicine in managing blood pressure.


Q: Do the side effects of Sinopril Co usually go away after a few weeks?

Regulatory documents indicate that certain effects, such as dizziness and a drop in blood pressure upon standing, are more likely to occur at the start of treatment or when a dose change is made. This time-related pattern indicates that these effects may be transient, or more noticeable when first starting the drug.


Q: Is it normal to feel a little dizzy when first starting Sinopril Co?

Yes, official data classifies dizziness as a common adverse reaction, affecting 1% to 10% of patients in studies. This effect is specifically noted to be more likely when treatment first begins, but is noted to be more likely at the start of treatment or during dose changes.


Q: Does Sinopril Co affect my mood or cause changes in feelings?

Regulatory documents list side effects related to the Nervous System and Psychiatric disorders in the uncommon or rare categories.


Q: Why do doctors often start with a low dose of Sinopril Co?

The combination product is typically reserved for patients whose high blood pressure is not adequately controlled by the individual components used alone. This means patients have generally already used and been titrated on the single ingredients before being switched to the fixed-dose combination.


Q: What is the general purpose of this combination?

The fixed-dose combination (FDC) provides a dual-action method for blood pressure management. It combines Lisinopril to relax and widen blood vessels (vasodilation) and Hydrochlorothiazide to help the body decrease circulating fluid volume, providing a strategy for managing high blood pressure through two different mechanisms.


Q: What is the difference between Sinopril Co and other 'sinopril'-style medicines?

Sinopril Co is a fixed-dose combination (FDC) that contains two active ingredients: Lisinopril (an ACE inhibitor) and Hydrochlorothiazide (a diuretic). Other 'sinopril'-style medicines are typically the single component (Lisinopril) only, without the added diuretic.


Q: Can Sinopril Co cause problems with sleeping?

Official adverse reaction data notes that insomnia (difficulty sleeping) has been reported in clinical studies as an uncommon side effect, meaning it may affect between 0.1% and 1% of patients.


Q: Are there any specific vitamins or supplements that should not be taken with Sinopril Co?

Official warnings state that potassium supplements and salt substitutes that contain potassium should generally be avoided. This is because co-administration creates a risk of significantly increasing potassium levels in the blood (hyperkalemia).


Q: Is it okay to drink alcohol while using Sinopril Co?

Official regulatory warnings indicate that alcohol may potentiate the hypotensive (blood pressure lowering) effects of the medicine. This means that alcohol intake may intensify the hypotensive effects of the medicine.


Q: Are there any food restrictions mentioned for people taking Sinopril Co?

The official instructions confirm that the medicine can be taken with or without food. However, foods high in potassium are subject to caution due to the interaction noted with potassium supplements.


Q: Is Sinopril Co safe for older adults (seniors)?

The medicine is officially approved for use in adult patients with hypertension. Specific caution is mentioned in regulatory documents regarding the elderly population when the drug is taken alongside NSAID pain relievers, due to an increased risk of kidney function changes.


Q: Can Sinopril Co be used by people with kidney issues?

Official documents state that the medicine is contraindicated for use in patients with severe renal impairment (a major kidney function issue). Its use is restricted in moderate renal impairment until the appropriate fixed dose is confirmed.


Q: Is Sinopril Co a medicine that needs to be taken long-term?

It is prescribed for the management of chronic high blood pressure, which is typically a long-term condition requiring ongoing treatment. Regulatory documents also note that the hydrochlorothiazide component carries a risk of Non-melanoma skin cancer with long-term use.


Q: If I miss a dose of Sinopril Co, what do official instructions suggest?

Official patient information advises that taking the dose as soon as possible is an option. However, if it is almost time for your next scheduled dose, the advice is to skip the missed dose and not take a double or extra dose to compensate.


Q: What happens if I stop taking Sinopril Co suddenly?

Stopping the medication should not be done suddenly, as abrupt discontinuation of ACE inhibitors can lead to a sudden, marked increase in blood pressure (rebound hypertension) and increased cardiovascular risk.


Q: What kind of research has been done on Sinopril Co?

The evidence reviewed by regulators primarily comes from Randomized Controlled Trials (RCTs) conducted in adults with essential high blood pressure, comparing the fixed-dose combination to the individual components and placebo, with a focus on short-term blood pressure reduction.


Q: Are there any studies comparing the effects of different doses of Sinopril Co?

The primary clinical evidence focuses on comparing the combination versus monotherapy. However, the approved fixed-dose options were determined based on regulatory review of the dose-response characteristics of the individual components.


Q: How does Sinopril Co influence kidney function?

The medicine is cautioned against in patients with existing kidney issues. The combination may cause deterioration of renal function when co-administered with NSAIDs, and its use is restricted in severe renal impairment.


Q: What does the term 'Angiotensin-Converting Enzyme Inhibitor' mean in simple language?

An Angiotensin-Converting Enzyme (ACE) Inhibitor is a type of medicine that blocks a natural substance (ACE) in the body that normally causes blood vessels to narrow. By blocking this, the medicine promotes the relaxation and widening of blood vessels, which helps to lower blood pressure.


Q: Does Sinopril Co require regular blood tests while using it?

Official patient information notes that lab and/or medical tests should be done while using the medication. These tests may include monitoring kidney function and checking blood potassium levels.


Q: Why might a person need to switch from one 'sinopril' medicine to Sinopril Co?

Official documentation indicates that the combination product is used when blood pressure is not adequately controlled by the single-ingredient lisinopril alone. Switching to the combination aims to enhance blood pressure management using two different mechanisms.


Q: Does taking Sinopril Co make a person sensitive to the sun?

The official label notes that the hydrochlorothiazide component is associated with an increased risk of Non-melanoma skin cancer with long-term use. Patients are generally advised to be aware of sun exposure due to the noted risks.


Q: Are there different forms of Sinopril Co, like tablets or capsules?

The product is supplied for oral use as a fixed-dose combination tablet. Official documents confirm it is available in multiple strength combinations of lisinopril and hydrochlorothiazide.


Q: Is Sinopril Co affected by other health conditions, like diabetes?

Yes, official warnings state that the medicine is contraindicated (should not be used) with the drug aliskiren in patients who also have diabetes mellitus or specific kidney issues.


Q: Do studies show a difference in how Sinopril Co affects different ethnic groups?

Regulatory documents mention that ACE inhibitors have been associated with a higher rate of angioedema (serious swelling) in black patients compared to non-black patients, a difference noted in clinical literature.


Q: Is Sinopril Co available without a prescription?

No, the medicine is classified by the government regulatory body for prescription-only use.


Q: Does Sinopril Co contain lactose or common allergens?

The list of inactive ingredients includes anhydrous lactose. It is also officially contraindicated for patients with hypersensitivity to either active component or any sulfonamide-derived drugs.


Q: How long has Sinopril Co been on the market?

The combination product (Lisinopril/Hydrochlorothiazide) received its Initial FDA approval date in February 1989.


Q: Is Sinopril Co known to cause issues with liver function?

Official safety documents report rare but serious adverse reactions that include hepatitis (liver inflammation), jaundice (yellowing of the skin or eyes), and elevated liver enzymes. Official documents describe the necessity of monitoring for signs of liver dysfunction.


Q: Does Sinopril Co have a 'Black Box Warning' from the FDA?

Yes, the medicine carries the FDA's Boxed Warning, which is the most serious level of warning. This warning specifically concerns the risk of fetal toxicity if the drug is taken during pregnancy.


Q: What is the half-life of Sinopril Co?

Official information on pharmacokinetics indicates that the elimination half-life of the lisinopril component is approximately 12.6 hours. This half-life is noted to be longer in patients with kidney impairment.

How should Sinopril Co be stored and disposed of?

The storage and disposal of Sinopril Co (Lisinopril/Hydrochlorothiazide) must strictly adhere to regulatory requirements to maintain product quality and safety.


Storage Requirements

Sinopril Co must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), and kept out of the reach of children. The medicine must be kept in the container it came in, tightly closed, and protected from excessive heat and moisture. It is specifically required that the product be kept from freezing.


Disposal Instructions

Unused or expired medicine should not be kept. Disposal must be performed in accordance with local regulations as advised by a pharmacist or healthcare professional. Do not dispose of the tablets by flushing them down a toilet or pouring them into a drain unless specifically permitted by an official take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinopril Co found in:

A-Z Index: